Senate panel bars use of state funds to buy opioid reversal drugs from companies tied to opioid litigation

Senate Bill 112, carried by Senator Yakovich, passed the Committee of the Whole on second reading by a 49-1 vote, prohibiting state funds (and available federal funds except as provided) from being used after June 30, 2025, to purchase opioid antagonists from a manufacturer or an affiliate that was a party to settlements or litigation tied to the opioid crisis.

Sponsor Yakovich said the bill aimed to avoid "paying the arsonist to put out his own fire," arguing the state should buy naloxone or similar products from manufacturers that did not profit from fueling the opioid epidemic. "All I'm asking is that our state not buy from those who caused the opioid crisis," Yakovich said, noting existing supply and that the change would not affect ongoing lawsuits or existing contracts.

Opponents raised concerns about supply continuity and unintended consequences for access to reversal drugs. Senator Ellsworth asked whether the statute could leave gaps if supplies or sources change; Yakovich and supporters said they had consulted the Department of Justice and testimony indicated alternate suppliers and distribution methods (including vending machines and other procurement routes) would be available.

Senator Newman, who works on opioid addiction and recovery issues, supported the bill and said testimony confirmed a sufficient supply of alternatives. "I like Senator Yakovich's analogy of, hiring an arsonist to put out a fire," Newman said, and urged colleagues to support the bill.

The clerk recorded 49 ayes and 1 nay. The committee reported SB 112 do pass on second reading.